VectorY to participate in key sector events in June 2024

Amsterdam, The Netherlands, June 14, 2024 – VectorY Therapeutics, a biotech company focusing on the development of innovative vectorized antibody approaches for the treatment of neurodegenerative diseases announces participation in the following events:

Sander Van Deventer, CEO will be attending the the ENCALS meeting 2024 to be held June 17-19 in Stockholm, Sweden, and Elena Ritsou, CCO will be attending the J.P. Morgan European Healthcare Symposium to be held June 20 in London, UK.

About VectorY

VectorY is on a mission to provide patients with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS. For more information, see www.vectorytx.com